(MedPage Today) — Novo Nordisk filed for FDA approval of its once-weekly GLP-1 receptor agonist Ozempic (semaglutide) at a higher dose of 2.0 mg. It’s currently available in 0.5-mg and 1-mg injectable dosing. (FiercePharma)
A small study found…
Source link
Comments are closed, but trackbacks and pingbacks are open.